Pharma & Biotech - Page 19

CVS Health’s pharmacy benefit manager Caremark has reached a settlement with the Federal Trade Commission over its use of rebates and the handling of TrumpRx purchases. Under the agreement, Caremark will count

Zhejiang Huahai Pharmaceutical has poached a senior quality executive from rival Jiangsu Hengrui Pharmaceuticals amid regulatory pressure on both Chinese drugmakers from the US Food and Drug Administration. The move signals an

Novo Nordisk has received European Commission marketing authorization for its Wegovy pill, giving the Danish drugmaker another significant head start over rival Eli Lilly. The approval covers adults with obesity or who

Advanced therapy supply chains are undergoing a fundamental transformation as regulatory expectations and patient-centric risk considerations continue to intensify across the industry. Adam Fox, Chief Quality and Regulatory Affairs Officer of Cryoport

Sanofi has filed two separate federal lawsuits against Moderna and Pfizer, alleging that several major Covid-19 and RSV vaccines infringe its mRNA delivery patents. The French pharmaceutical giant, listed on US markets

Cryoport Systems is repositioning the conversation around supply chains for advanced therapies, arguing that quality must be embedded from the ground up rather than applied as an afterthought. Adam Fox, Chief Quality

Merck (MRK) has announced that its flagship cancer drug Keytruda has achieved a landmark result in the treatment of a specific endometrial cancer subtype. The drug became the first PD-1 inhibitor to

Pharma’s third-party logistics sector is undergoing a fundamental transformation, moving well beyond its traditional role of shifting pallets through wholesale distribution chains. The industry is now contending with smaller patient populations, highly

Celcuity has secured FDA approval for gedatolisib, now branded as Revtorpyk, marking a significant milestone in the treatment of hormone receptor-positive, HER2-negative breast cancer. The regulator approved Revtorpyk specifically for previously treated

The Trump administration’s April 2026 announcement of a 100% base levy on imported APIs and patented drugs has forced a sweeping re-evaluation of pharmaceutical supply chains across the industry. Reshoring pharmaceutical manufacturing